eMIMS New Product
New drug - Tyverb
29-Jul-08
Tyverb (lapatinib) is an oral antineoplastic agent that may provide women with an alternative option when other breast cancer treatments have failed.
Tyverb is indicated in combination with capecitabine for advanced or metastatic breast cancer in patients whose tumours overexpress ErbB2 (HER2). Patients should have progressive disease following prior therapy that included anthracyclines and taxanes and trastuzumab in the metastatic setting.
Lapatinib has a 'conditional licence' which is valid for 1 year and requires GSK to provide further trial data. A conditional licence is granted when a drug fulfils an unmet medical need and the benefit to public health outweighs the risk that additional data are still required.
View Tyverb drug record
Further information: GSK 0800 221441
Quick search - use * for an abbreviated search, eg nico*
Tools
Related Articles
Related Guidelines
Related Fact Sheets
Related Drugs By Area
Latest Guidelines
- Osteoporotic Fragility Fractures in Postmenopausal Women: Primary Prevention (NICE)
- Osteoporotic Fragility Fractures in Postmenopausal Women: Secondary Prevention (NICE)
- VTE, Prevention of: Dabigatran (NICE)
- Influenza Prophylaxis: Oseltamivir, Amantadine and Zanamivir (NICE)
- Hepatitis B, Chronic: Entecavir (NICE)
GMS Contract Action Plan
Jobs
Job of the Week
- Saturday Morning Locum North East England
- Full time salaried GP South East England
- Salaried GP
- Salaried GPs South East England
- Part-Time Salaried GP South East England
- GP Positions North West England
- General Practice Placements Central London
- Salaried GP West Midlands
- Part Time Salaried GP South West England
- Salaried Doctor East of England
Comments
Only registered users may comment. Log in now or register for a free account.